Tirzepatide and cholesterol — March 2026

This one has a reasonably settled answer, so here it is. The GIP arm is doing real work rather than padding the label. GIP receptor agonism appears to improve adipose insulin sensitivity and lipid handling, and — counter-intuitively — GIP signalling in the CNS reduces nausea rather than adding to it, which is why tolerability at high total agonism is better than the GLP-1-only comparison would predict. SURPASS-2 is the cleanest head-to-head: tirzepatide beat semaglutide 1mg at every dose tier.

COA_Karl said:

The GIP arm is doing real work rather than padding the label.

Agreed on the mechanism, with the caveat that the head-to-head used semaglutide 1mg, not 2.4mg. It is still the best direct evidence available, but it is not the comparison most people think they are citing.

Happy to go further on any of that.

paige_pharma said:

Trying to work out whether my panel improved or merely rearranged itself, because two of the numbers went the wrong way.

True, though the ladder is longer and that is not a neutral detail — six dose steps means six opportunities to stall on the way up, and plenty of people never reach the dose the headline number came from.

Happy to go further on any of that.

Clinical perspective, offered as context rather than as advice.

Comprehensive lipid panel update relevant to the lipid panel:

The triglyceride drop is the most impressive. My cardiologist reduced my statin dose based on these results.